Autres langues Kamada Ltd.

Actions

KMDA

IL0010941198

Produits pharmaceutiques

Marché Fermé - TEL AVIV STOCK EXCHANGE 13:25:37 28/09/2026			Varia. 5j.	Varia. 1 janv.
2 648,00 ^ILa	-0,68%		+0,57%	+17,17%

17/09	Kamada confirme disposer de stocks suffisants de Kedrab pour répondre à la hausse de la demande aux États-Unis	CI
17/09	Kamada maintient un approvisionnement et une capacité de production 'suffisants' pour le KedRAB face à la hausse des cas d'exposition à la rage aux États-Unis	MT

Autres langues

17/09	Kamada Confirms Sufficient Kedrab Supply to Meet Increased Demand in the United States
17/09	Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US
17/09	CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
10/09	Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
06/09	Kamada : Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
03/09	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
03/09	Kamada Ltd. Obtains Israel Tax Authority Ruling on Withholding Tax Procedures for $9.8 Million Cash Dividend to Shareholders
18/08	Kamada Declares Cash Dividend of $0.17 per Share, the Company Reported Record-High Revenue and Profitability for First Six Months of 2026
17/08	Kamada Lowers Quarterly Dividend to $0.17 a Share; Payable Sept. 17 to Holders of Record Aug. 27
17/08	Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
17/08	Kamada Ltd. Declares Cash Dividend, Payable on September 17, 2026
12/08	Kamada Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Kamada's Finance Chief Chaime Orlev to Step Down
12/08	Kamada: Q2 Earnings Snapshot
12/08	Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
12/08	Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2026
12/08	Kamada Announces Planned Transition of Chief Financial Officer
12/08	Chaime Orle Plans to Resign as Chief Financial Officer of Kamada Ltd, Effective December 31, 2026
05/08	Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
20/07	Kamada Ltd Announces Three-Year USD 50 Million Supply Agreement To Supply Plasma To Biopharmaceutical Company Focused On Plasma-Derived Therapies
20/07	Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm
20/07	Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
13/07	Kamada Ltd. Highlights CYTOGAM Study Results Presented at The 2026 ISHLT Annual Meeting
13/07	Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
01/06	Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory